Vaccine Therapy of B Cell Malignancies: Different Strategies for a Novel Approach
- 1 January 2001
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 42 (5) , 881-889
- https://doi.org/10.3109/10428190109097707
Abstract
This review deals with the theoretical principles and experimental results of immunotherapy for B cell malignancies, namely for non-Hodgkin lymphomas (NHLs) and multiple myeloma. Its focus is the use of vaccines in clinical practice with particular emphasis on the most recent developments and therapeutic opportunities arising from combination therapies. Previous studies will be reviewed and the present status of vaccine technology summarized.Keywords
This publication has 33 references indexed in Scilit:
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myelomaInternational Journal of Cancer, 1999
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Cancer vaccinesNature Medicine, 1998
- B cells inhibit induction of T cell-dependent tumor immunityNature Medicine, 1998
- Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsetsBritish Journal of Haematology, 1997
- DNA immunization induces protective immunity against B–cell lymphomaNature Medicine, 1996
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphomaNature, 1993
- Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their TumorsNew England Journal of Medicine, 1992